Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Conclusion: Combination therapy with acalabrutinib + BR showed an acceptable safety profile, with no meaningful changes in acalabrutinib exposure. The high CR rate with acalabrutinib + BR in both TN and R/R MCL further supports a phase 3 randomized study of acalabrutinib + BR versus BR in TN MCL (NCT02972840).DisclosuresPhillips: Bayer: Consultancy; Seattle Genetics: Consultancy; Pharmacyclics: Consultancy, Research Funding; Abbvie: Research Funding; Genentech: Consultancy; Gilead: Consultancy. Smith: Portola: Research Funding; Merck Sharpe Dohme and Corp: Consultancy, Research Funding; Acerta Pharma BV: Research Funding; Pharmacyclics: Research Funding; Genentech: Research Funding; Seattle Genetics: Research Funding. Jurczak: Afimed: Research Funding; BeiGene: Research Funding; Celgene: Research Funding; Epizyme: Research Funding; Gilead: Research Funding; Janssen: Research Funding; Nordic Nanovector: Research Funding; Merck: Research Funding; Morphosys: Research Funding; Pharmacyclics: Research Funding; Servier: Research Funding; Roche: Research Funding; TG Therapeutics: Research Funding; Gilead: Consultancy; Janssen: Consultancy; Sandoz-Nowartis: Consultancy; AstraZeneca/Acerta: Consultancy, Research Funding; European Medicines Agency: Consultancy. Robak: AbbVie, Inc: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy; Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Stevens: Bayer: Consultan...
Source: Blood - Category: Hematology Authors: Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster III Source Type: research